USS Investment Management Ltd Acquires 306,648 Shares of DexCom, Inc. $DXCM

USS Investment Management Ltd lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 342.7% in the first quarter, Holdings Channel.com reports. The fund owned 396,128 shares of the medical device company’s stock after purchasing an additional 306,648 shares during the period. USS Investment Management Ltd’s holdings in DexCom were worth $24,879,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Trust Co. of Vermont raised its holdings in DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after purchasing an additional 145 shares in the last quarter. CVA Family Office LLC boosted its stake in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after purchasing an additional 178 shares in the last quarter. Keel Point LLC increased its position in shares of DexCom by 3.1% during the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock valued at $430,000 after buying an additional 193 shares during the period. Finally, Integrated Wealth Concepts LLC increased its position in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after buying an additional 196 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In related news, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director owned 52,852 shares in the company, valued at $3,917,918.76. This represents a 7.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director directly owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. This trade represents a 3.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 46,694 shares of company stock valued at $3,343,977. 0.28% of the stock is currently owned by insiders.

DexCom Stock Down 3.8%

Shares of DexCom stock opened at $67.35 on Wednesday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The firm has a market cap of $25.99 billion, a price-to-earnings ratio of 28.78, a PEG ratio of 1.15 and a beta of 1.45. The company has a 50-day moving average of $67.89 and a 200 day moving average of $68.12. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. DexCom’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 earnings per share. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the stock. Evercore upgraded shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective for the company in a report on Tuesday, March 24th. Barclays reiterated an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Stifel Nicolaus set a $90.00 target price on DexCom and gave the company a “buy” rating in a research note on Friday, June 5th. Finally, Sanford C. Bernstein set a $77.00 price target on DexCom in a research report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $84.88.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.